Literature DB >> 8895286

A comparison of variable-dose patient-controlled analgesia with fixed-dose patient-controlled analgesia.

D R Love1, H Owen, A H Ilsley, J L Plummer, R M Hawkins, A Morrison.   

Abstract

We examined the effect on the quality of analgesia and side effects of increasing the patient control component of morphine patient-controlled analgesia (PCA) by offering the patient a choice of bolus dose sizes. Using a three-button hand piece, patients could choose between 0.5-, 1.0-, and 1.5-mg boluses of morphine (variable-dose PCA, VDPCA). Successful demands were delivered by a modified Graseby 3400 Anaesthesia Pump controlled by a Toshiba T1900 computer. This system was compared with conventional fixed-dose PCA (FDPCA) (1.0 mg of morphine) delivered by a Graseby 3300 PCA Pump. Both treatment groups had a 5-min lockout interval. Sixty patients were randomly assigned to receive either VDPCA or FDPCA after major abdominal gynecological surgery or hip or knee arthroplasty. Treatment groups did not differ in their duration of PCA therapy, total morphine consumption, or time spent with mild or severe oxyhemoglobin desaturation. There were no differences in their ease of controlling pain, satisfaction with pain control, experience of pain on movement, quality of sleep, severity of nausea, or incidence of vomiting. Although the more complex VDPCA technique provides adequate postoperative analgesia, it does not offer any advantage over conventional FDPCA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895286     DOI: 10.1097/00000539-199611000-00028

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  2 in total

1.  Modifiers of Patient-Controlled Analgesia Efficacy in Acute and Chronic Pain.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

2.  Pain model and fuzzy logic patient-controlled analgesia in shock-wave lithotripsy.

Authors:  J S Shieh; L W Chang; M S Wang; W Z Sun; Y P Wang; Y P Yang
Journal:  Med Biol Eng Comput       Date:  2002-01       Impact factor: 2.602

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.